Abstract: A device for providing a droplet of a liquid stored in an interior of a vial is disclosed that includes a support body and a resilient dome portion mounted to the support body to form a chamber having air, with the dome portion being configured to create an air flow when activated by compression. The support body includes a vial seat, a nozzle, and air flow and transfer conduits. The support body is arranged, when the vial is received by the vial seat, such that the air flow conduit establishes an air connection between the vial interior and the chamber, the transfer conduit establishes a fluid connection between the vial and the nozzle, and, upon activation of the dome portion, the air flow delivers air into the vial that causes liquid to be transferred from the vial to the nozzle through the transfer conduit.

Abstract: A device for transferring a liquid from a first vial to a second vial is disclosed having a dome portion configured to create an air flow when activated by compression and re-expansion, and a support body tightly supporting the dome portion to form a chamber with air therein. The support body includes first and second vial seats, and a transfer conduit. The first and second vial seats are arranged to receive the first and second vials. When the first and second vials are received in the first and second vial seats, the transfer conduit is arranged to establish a fluid connection between the first vial and the second vial. Upon activation of the dome portion, air is delivered into the first vial, thereby creating a pressure rise in the first vial which causes the liquid to transfer from the first vial to the second vial through the transfer conduit.

Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: A device for treating air with alpha radioisotope ionization, comprising a frame having an internal surface, the internal surface defining an internal space, a pair of internal brackets arranged within the internal space and removably connected to the frame, each internal bracket arranged to have at least one spacer arranged between the respective bracket and the internal surface of the frame, and at least one alpha ionizing apparatus removably connected to the pair of internal brackets.

Abstract: Provided herein are antibody-drug conjugates that bind EGFR, in particular human EGFR, their methods of making, and their uses to treat patients having cancer.

Abstract: Provided herein are antibody-drug conjugates that bind EGFR, in particular human EGFR, their methods of making, and their uses to treat patients having cancer.

Abstract: Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions. The invention further provides compositions and crystals of an erythropoietin receptor in complex with an anti-erythropoietin receptor antibody. Specifically, the high-resolution structure provides binding sites defined by the structure coordinated determined herein.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies and antigen-binding portions, methods of treatment, as well as pharmaceutical compositions comprising said antibodies and antigen-binding portions.